RxDoctor Payments Data

Nilamben Shah, MD

Internal Medicine · Saint Petersburg, FLNPI 1356306070

Payments from drug & device makers

$464in general payments, 2019–2025

Across 28 payments — averaging $16.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$227
  • Novartis$95
  • Pfizer$68
  • Axonics, Inc.$38
  • AstraZeneca$36

What the payments were for

  • Food & beverage$464100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk15$227
Novartis5$95
Pfizer4$68
Axonics, Inc.2$38
AstraZeneca2$36

How this compares

$464 in reported general payments places this provider in the 55th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$479,663
Medicare patients
598
Services billed
5,610

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban622$288,627
OzempicSemaglutide106$148,995
JanuviaSitagliptin Phosphate117$80,345
TrulicityDulaglutide59$72,062
NuplazidPimavanserin Tartrate28$69,597
XareltoRivaroxaban112$59,275
JardianceEmpagliflozin37$39,394
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$38,060
DovatoDolutegravir Sodium/Lamivudine11$37,484
RexultiBrexpiprazole36$30,852
MounjaroTirzepatide31$29,523
EntrestoSacubitril/Valsartan47$24,268
FarxigaDapagliflozin Propanediol35$18,665
Ergotamine-CaffeineErgotamine Tartrate/Caffeine11$17,896
LinzessLinaclotide23$15,897

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$68$288,627622 claims
Novo NordiskOzempic$227$148,995106 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$36$43,02791 claims
NovartisEntresto$95$24,26847 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Saint Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →